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suspected. Patients and Methods: Six male and 2 female patients
with hematologic malignancies, median age 45 (22-55) years, re-
ceiving unrelated stem cell transplants in our institution within the
last 6 years, experienced primary (n 5) or secondary (n 3) graft
failure. Match was 7/8 in one, 8/8 in three, 8/10 in three and 9/10
in one case. Primary conditioning was myeloablative in all patients
and included rabbit ATG either Genzyme or Fresenius in all but
one. Graft source was bone marrow in 7 and PBSC in one case,
respectively. Mechanism of graft failure was evaluated by morphol-
ogy, immunophenotyping, chimerism and kinetics and was judged
rejection in three and probably immunologically mediated in 5
cases. At a median of 42 (35-71) days following the ﬁrst transplant
7 patients received PBSC and one patient bone marrow as a second
transplant, 4 from the same and 4 from a different unrelated donor.
Matches of the new donors were 6/8, 7/8, 8/10 and 10/10. Two
earlier patients were given ﬂudarabin 100 and 120 mg/m2 com-
bined with ATG Genzyme 5 mg/kg BW, the later ones ﬂudarabin
150 mg/m2 together with ATG 7.5 mg/kg BW. Results: Seven out
of 8 patients engrafted at a median of 14 days after second and 58
days after ﬁrst transplant. One non-engraftment occurred in a
polytransfused patient with refractory anemia and primary rejec-
tion, after reconditioning with ﬂudarabin 100 mg/m2 and ATG 5
mg/kg BW and grafting with the same donor. At a median obser-
vation time of 555 (266-2020) days 4 patients are alive and well.
Four patients died at a median of 135 (75-337) days: two from
relapse, one from aGvHD °IV and one from fungal sepsis. Con-
clusion: In primary and secondary graft failure after allogeneic
stem cell transplantation, for reconditioning a highly immunosup-
pressive regimen with limited toxicity is warranted. Fludarabin 150
mg/m2 and ATG Genzyme 7.5 mg/kg BW is a very efﬁcient and
well tolerated combination enabling engraftment even across a two
HLA antigen barrier.
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COSTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
Svahn, B.-M.B.M.S.1,2, Alvin, O.O.A.3, Ringden, O.O.R.1,2,
Gardulf, A.A.G.2, Remberger, M.M.R.2 1Center for Allogeneic Stem
Cell Transplantation, Karolinska University Hospital/Huddinge, Stock-
holm, Sweden; 2Department of Laboratory Medicine, Division of Clinical
Immunology, Karolinska Institutet, Stockholm, Sweden; 3Department of
Internal Auditing, Karolinska Institutet, Stockholm, Sweden.
Purpose: To determine the total costs after allogeneic hemato-
poietic stem cell transplantation (ASCT) and the pre- and post-
transplant conditions or factors associated with increases or de-
creases in costs. Patients and Methods: We collected all in- and
outpatient costs during ﬁve years in 93 patients who had under-
gone ASCT in 1998 and 1999 at Huddinge University Hospital in
Stockholm, Sweden. The inpatient costs included all those related
to a patient from the ﬁrst day of admission until discharge and then
all costs of readmission to any hospital in the Stockholm area.
Results: The total median cost of ﬁve posttransplant years was
163675.61 (61160.87-405790.22) USD. The costs were highest
during the ﬁrst year—i.e., median inpatient and outpatient costs
118165.68 USD and 15339.82 USD, respectively. The total costs
during the ﬁrst year were higher in patients with acute graft-
versus-host disease grades III-IV (relative hazards [RH] 1.35, P 
.003), bacteremia (RH 1.33, P  .005), veno-occlusive disease of
the liver (RH 1.32, P .005), prophylaxis with granulocyte colony-
stimulating factor (G-CSF; RH 1.31, P .01), acute leukemia (RH
1.32, P  .008) and treatment in hospital instead of at home (RH
1.20, P  .07). During the early transplant period, a second
transplantation (RH 1.35, P .004) and hemorrhagic cystitis (HC)
(RH 1.24, P  .03) were also associated with higher costs. The
total ﬁve-year cost declined with longer survival rates (r  0.4028,
P  .001) and reduced intensity conditioning (RH 0.79, P  .024).
Conclusion: Higher costs of ASCT were associated with retrans-
plantation, acute leukemia, G-CSF prophylaxis, hospital care, my-
eloablative conditioning and major transplant-related complica-
tions.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) USING FLU-
DARABINE, BUSULFAN AND THYMOGLOBULIN: A MATCHED COMPAR-
ISON TO HCT WITH BUSULFAN AND CYCLOPHOSPHAMIDE
Bredeson, C.1,2, Kurian, S.1, Zhang, M.-J.1, Muehlenbein, C.1,
Nugent, M.1, Brown, C.3, Stewart, D.3, Savoie, L.3, Bahlis, N.3,
Chaudhry, A.3, Quinlan, D.3, Russell, J.3, Horowitz, M.M.1 1The
Center for International Blood and Marrow Transplant Research, Med-
ical College of Wisconsin, Milwaukee, WI; 2Cancer Care Manitoba,
Winnipeg, MB, Canada; 3The Alberta Blood and Marrow Transplant
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Allogeneic HCT after standard myeloablative conditioning is
associated with signiﬁcant risks of regimen related mortality and
graft versus host disease (GVHD). Over the past 5 years, a novel
ﬂudarabine-based conditioning regimen using a low dose of rabbit
ATG (Thymoglobulin) with ﬂudarabine and intravenous busulfan
has been used at The Alberta Blood and Marrow Transplant
Program in Calgary. Initial data suggest a lower incidence of acute
GvHD with this approach in a diverse population of patients with
acute leukemia (n  48), chronic myelogenous leukemia (n  21),
chronic lymphocytic leukemia (n  9), myelodysplasia (n  22),
lymphoma (n  23) and multiple myeloma (n  11). To assess
further this single center experience, we performed a retrospective
analysis comparing their outcomes with matched controls receiv-
ing HCT after conditioning with standard busulfan and cyclophos-
phamide during the same time period. We attempted to select two
controls for each case from 574 eligible patients reported to the
CIBMTR. All patients were 18 to 65 years of age, received HLA-
identical sibling peripheral blood or bone marrow transplants for
the diseases noted above from 1999-2003 and were given cyclo-
sporine and methotrexate for GVHD prophylaxis. Controls were
selected to match on disease and disease status at transplant and to
minimize age differences. Two matches were found for 95 cases, 1
for 26 and none for 13. The latter 13 were excluded from further
study leaving 121 cases and 216 matched controls available for
comparison. Median follow-up was 30 (range, 12-61) months for
cases and 35 (range, 2-72) months for controls (P  .47). Com-
pared to the 216 controls, the 121 cases had lower Karnofsky scores
before transplant, and were more likely to receive a peripheral
blood transplant. Outcome comparisons used multivariate Cox
regression, stratiﬁed on the matched pair, to adjust for these
differences. The risk of grades II-IV acute GvHD (relative risk
[RR] 0.34, 95% conﬁdence interval [CI], 0.20-0.59, P .0001) and
overall mortality (RR 0.48, CI, 0.29-0.77, P  .003) were signiﬁ-
cantly lower in cases versus controls. The risk of chronic GvHD
was similar in the cases and controls. These results suggest that the
novel regimen ﬂudarabine, busulfan and Thymoglobulin decreases
the risk of acute GvHD and improves survival after HLA-identical
sibling HCT and support the development of a prospective multi-
center randomized clinical trial to conﬁrm these ﬁndings.
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LOW TREATMENT RELATED MORTALITY AND IMPROVED SURVIVAL IN
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT: TAR-
GETED INTRAVENOUS BUSULFAN COMBINED WITH FLUDARABINE
(tBuFlu) AS CONDITIONING REGIMEN
Field, T.L., Perkins, J., Alsina, M., Ayala, E., Fancher, K., Janssen, W.,
Perez, L., Sullivan, D., Tate, C., Anasetti, C. H. Lee Mofﬁtt Cancer
Institute, Tampa, FL.
Myeloablative doses of intravenous busulfan in combination with
ﬂudarabine have been employed as conditioning before hemato-
poietic cell allografts with reduced treatment-related toxicity and
mortality. In this report, we describe the early results of a targeted
busulfan pharmacokinetic dosing strategy (tBuFlu) used in combi-
nation with ﬂudarabine before either related or unrelated grafts
We treated 61 pts with tBuFlu prior to allogeneic peripheral blood
stem cell transplantation. The median patient age was 48 (range
22-68) years. Patient diagnoses included AML (13 de novo, 7 with
prior MDS, and 7 treatment related), MDS (7 pts), MF (5), NHL
(6 pts), ALL (6 pts), CML (5 pts), CLL (2), MM (2) and PNH (1).
Five patients had received a prior autologous HCT. Donors were
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